Report Overview
Report Summary
The global Immune Globulin Intravenous market is valued at million US$ in 2020 and will reach million US$ by the end of 2027, growing at a CAGR of during 2021-2027. The objectives of this study are to define, segment, and project the size of the Immune Globulin Intravenous market based on company, product type, end user and key regions.
This report studies the global market size of Immune Globulin Intravenous in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Immune Globulin Intravenous in these regions.
This research report categorizes the global Immune Globulin Intravenous market by top players/brands, region, type and end user. This report also studies the global Immune Globulin Intravenous market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Baxter
Grifols
CSL
Octapharma
Biotest
Kedrion
Hualan Bio
CNBG
Shanghai RAAS
CBPO
LFB Group
BPL
Sichuan Yuanda Shuyang
Market size by Product
IVIg Liquid
IVIg Powder
Market size by End User
Immunodeficiency
Autoimmune Disease
Acute Infection
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Immune Globulin Intravenous market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2020, and forecast to 2027.
To understand the structure of Immune Globulin Intravenous market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Immune Globulin Intravenous companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Immune Globulin Intravenous submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Immune Globulin Intravenous are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2020
Forecast Year 2021 to 2027
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Immune Globulin Intravenous market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table Of Contents
Table Of Contents
Table of Contents
1 Study Coverage
1.1 Immune Globulin Intravenous Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Immune Globulin Intravenous Market Size Growth Rate by Product
1.4.2 IVIg Liquid
1.4.3 IVIg Powder
1.5 Market by End User
1.5.1 Global Immune Globulin Intravenous Market Size Growth Rate by End User
1.5.2 Immunodeficiency
1.5.3 Autoimmune Disease
1.5.4 Acute Infection
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Immune Globulin Intravenous Market Size
2.1.1 Global Immune Globulin Intravenous Revenue 2017-2027
2.1.2 Global Immune Globulin Intravenous Sales 2017-2027
2.2 Immune Globulin Intravenous Growth Rate by Regions
2.2.1 Global Immune Globulin Intravenous Sales by Regions
2.2.2 Global Immune Globulin Intravenous Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 Immune Globulin Intravenous Sales by Manufacturers
3.1.1 Immune Globulin Intravenous Sales by Manufacturers
3.1.2 Immune Globulin Intravenous Sales Market Share by Manufacturers
3.1.3 Global Immune Globulin Intravenous Market Concentration Ratio (CR5 and HHI)
3.2 Immune Globulin Intravenous Revenue by Manufacturers
3.2.1 Immune Globulin Intravenous Revenue by Manufacturers (2017-2020)
3.2.2 Immune Globulin Intravenous Revenue Share by Manufacturers (2017-2020)
3.3 Immune Globulin Intravenous Price by Manufacturers
3.4 Immune Globulin Intravenous Manufacturing Base Distribution, Product Types
3.4.1 Immune Globulin Intravenous Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Immune Globulin Intravenous Product Type
3.4.3 Date of International Manufacturers Enter into Immune Globulin Intravenous Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Immune Globulin Intravenous Sales by Product
4.2 Global Immune Globulin Intravenous Revenue by Product
4.3 Immune Globulin Intravenous Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global Immune Globulin Intravenous Breakdown Data by End User
6 North America
6.1 North America Immune Globulin Intravenous by Countries
6.1.1 North America Immune Globulin Intravenous Sales by Countries
6.1.2 North America Immune Globulin Intravenous Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Immune Globulin Intravenous by Product
6.3 North America Immune Globulin Intravenous by End User
7 Europe
7.1 Europe Immune Globulin Intravenous by Countries
7.1.1 Europe Immune Globulin Intravenous Sales by Countries
7.1.2 Europe Immune Globulin Intravenous Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Immune Globulin Intravenous by Product
7.3 Europe Immune Globulin Intravenous by End User
8 Asia Pacific
8.1 Asia Pacific Immune Globulin Intravenous by Countries
8.1.1 Asia Pacific Immune Globulin Intravenous Sales by Countries
8.1.2 Asia Pacific Immune Globulin Intravenous Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Immune Globulin Intravenous by Product
8.3 Asia Pacific Immune Globulin Intravenous by End User
9 Central & South America
9.1 Central & South America Immune Globulin Intravenous by Countries
9.1.1 Central & South America Immune Globulin Intravenous Sales by Countries
9.1.2 Central & South America Immune Globulin Intravenous Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Immune Globulin Intravenous by Product
9.3 Central & South America Immune Globulin Intravenous by End User
10 Middle East and Africa
10.1 Middle East and Africa Immune Globulin Intravenous by Countries
10.1.1 Middle East and Africa Immune Globulin Intravenous Sales by Countries
10.1.2 Middle East and Africa Immune Globulin Intravenous Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Immune Globulin Intravenous by Product
10.3 Middle East and Africa Immune Globulin Intravenous by End User
11 Company Profiles
11.1 Baxter
11.1.1 Baxter Company Details
11.1.2 Company Business Overview
11.1.3 Baxter Immune Globulin Intravenous Sales, Revenue and Gross Margin (2017-2020)
11.1.4 Baxter Immune Globulin Intravenous Products Offered
11.1.5 Baxter Recent Development
11.2 Grifols
11.2.1 Grifols Company Details
11.2.2 Company Business Overview
11.2.3 Grifols Immune Globulin Intravenous Sales, Revenue and Gross Margin (2017-2020)
11.2.4 Grifols Immune Globulin Intravenous Products Offered
11.2.5 Grifols Recent Development
11.3 CSL
11.3.1 CSL Company Details
11.3.2 Company Business Overview
11.3.3 CSL Immune Globulin Intravenous Sales, Revenue and Gross Margin (2017-2020)
11.3.4 CSL Immune Globulin Intravenous Products Offered
11.3.5 CSL Recent Development
11.4 Octapharma
11.4.1 Octapharma Company Details
11.4.2 Company Business Overview
11.4.3 Octapharma Immune Globulin Intravenous Sales, Revenue and Gross Margin (2017-2020)
11.4.4 Octapharma Immune Globulin Intravenous Products Offered
11.4.5 Octapharma Recent Development
11.5 Biotest
11.5.1 Biotest Company Details
11.5.2 Company Business Overview
11.5.3 Biotest Immune Globulin Intravenous Sales, Revenue and Gross Margin (2017-2020)
11.5.4 Biotest Immune Globulin Intravenous Products Offered
11.5.5 Biotest Recent Development
11.6 Kedrion
11.6.1 Kedrion Company Details
11.6.2 Company Business Overview
11.6.3 Kedrion Immune Globulin Intravenous Sales, Revenue and Gross Margin (2017-2020)
11.6.4 Kedrion Immune Globulin Intravenous Products Offered
11.6.5 Kedrion Recent Development
11.7 Hualan Bio
11.7.1 Hualan Bio Company Details
11.7.2 Company Business Overview
11.7.3 Hualan Bio Immune Globulin Intravenous Sales, Revenue and Gross Margin (2017-2020)
11.7.4 Hualan Bio Immune Globulin Intravenous Products Offered
11.7.5 Hualan Bio Recent Development
11.8 CNBG
11.8.1 CNBG Company Details
11.8.2 Company Business Overview
11.8.3 CNBG Immune Globulin Intravenous Sales, Revenue and Gross Margin (2017-2020)
11.8.4 CNBG Immune Globulin Intravenous Products Offered
11.8.5 CNBG Recent Development
11.9 Shanghai RAAS
11.9.1 Shanghai RAAS Company Details
11.9.2 Company Business Overview
11.9.3 Shanghai RAAS Immune Globulin Intravenous Sales, Revenue and Gross Margin (2017-2020)
11.9.4 Shanghai RAAS Immune Globulin Intravenous Products Offered
11.9.5 Shanghai RAAS Recent Development
11.10 CBPO
11.10.1 CBPO Company Details
11.10.2 Company Business Overview
11.10.3 CBPO Immune Globulin Intravenous Sales, Revenue and Gross Margin (2017-2020)
11.10.4 CBPO Immune Globulin Intravenous Products Offered
11.10.5 CBPO Recent Development
11.11 LFB Group
11.12 BPL
11.13 Sichuan Yuanda Shuyang
12 Future Forecast
12.1 Immune Globulin Intravenous Market Forecast by Regions
12.1.1 Global Immune Globulin Intravenous Sales Forecast by Regions 2021-2027
12.1.2 Global Immune Globulin Intravenous Revenue Forecast by Regions 2021-2027
12.2 Immune Globulin Intravenous Market Forecast by Product
12.2.1 Global Immune Globulin Intravenous Sales Forecast by Product 2021-2027
12.2.2 Global Immune Globulin Intravenous Revenue Forecast by Product 2021-2027
12.3 Immune Globulin Intravenous Market Forecast by End User
12.4 North America Immune Globulin Intravenous Forecast
12.5 Europe Immune Globulin Intravenous Forecast
12.6 Asia Pacific Immune Globulin Intravenous Forecast
12.7 Central & South America Immune Globulin Intravenous Forecast
12.8 Middle East and Africa Immune Globulin Intravenous Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Immune Globulin Intravenous Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer